KRAS and non-small cell lung carcinoma: Given its relative safety and a hint at moderate single agent activity, defactinib is currently being evaluated with avutometinib (VS-6766), an inhibitor of RAS-RAF-MEK-ERK signaling, in a phase II trial dubbed RAMP-202, in KRAS-mutated NSCLC patients after the failure of prior platinum-based chemotherapy and checkpoint inhibition [61].